Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Huya Bioscience has completed three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 or Sulcardine sulphate.
Subscribe to our email newsletter
The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias.
Preclinical data developed by Huya and its Chinese partner, along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias.
Company has reported the formation of clinical advisory team for its new anti-arrhythmic compound. The advisory team consists of world-class biomedical researchers who will provide guidance to Huya and its Chinese partner, Shanghai Institute of Materia Medica (SIMM), throughout the course of an innovative US/China co-development process for HBI-3000.